Trump Purchased Up to $680K in Eli Lilly Stock as Administration Advanced GLP-1-Friendly Policies
Federal ethics disclosures released May 14, 2026, revealed that President Donald Trump bought between $415,000 and $680,000 in Eli Lilly stock across seven purchases between January and March 2026, while his administration simultaneously advanced policies that benefited the GLP-1 drugmaker.
Policy Actions That Benefited Lilly During the Trading Window
- Medicare GLP-1 Bridge ($50/month): CMS proposed the BALANCE/Bridge pilot program; manufacturer application deadline was January 8. Lilly was named a participating manufacturer.
- FDA Foundayo Approval (April 1): Approved under Commissioner Makary's National Priority Voucher program in just 50 days — Makary touted "eliminating delays."
- TrumpRx portal (February): Government website directing patients to lower-price GLP-1s, featuring Zepbound at $299/month and pointing to LillyDirect.
- Compounded GLP-1 crackdown (February): FDA intensified enforcement against cheaper compounded alternatives to Lilly's branded products.
Ethics Concerns
- Trump also purchased $250K–$500K in West Pharmaceutical Services stock (Feb 10), a manufacturer of injectable devices whose GLP-1 business drove recent revenue growth
- The Trump Organization claims independent brokers control the investments and that neither Trump nor his children "select, direct, or approve" specific trades
- Legal ethicist Kathleen Clark noted the appearance of conflict on two fronts: public should believe government actions are motivated by common good, not enrichment, and that officials aren't benefiting from inside information
Stock Context
Lilly finished 2025 with $65 billion in revenue, up $20 billion YoY, and guided to above $80 billion for 2026. TD Cowen analysts explicitly noted that guidance "anticipates favorable impact from Medicare coverage of obesity medications by 7/1/26."